Tocqueville Asset Management’s BioXcel Therapeutics BTAI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-738
| Closed | -$4.41K | – | 516 |
|
|
2024
Q4 | $4.41K | Sell |
738
-6
| -0.8% | -$36 | ﹤0.01% | 535 |
|
|
2024
Q3 | $7.26K | Sell |
744
-1,990
| -73% | -$19.4K | ﹤0.01% | 526 |
|
|
2024
Q2 | $56K | Sell |
2,734
-282
| -9% | -$5.78K | ﹤0.01% | 520 |
|
|
2024
Q1 | $136K | Sell |
3,016
-125
| -4% | -$5.64K | ﹤0.01% | 520 |
|
|
2023
Q4 | $148K | Buy |
3,141
+666
| +27% | +$31.4K | ﹤0.01% | 499 |
|
|
2023
Q3 | $100K | Hold |
2,475
| – | – | ﹤0.01% | 494 |
|
|
2023
Q2 | $264K | Buy |
2,475
+162
| +7% | +$17.3K | ﹤0.01% | 467 |
|
|
2023
Q1 | $690K | Sell |
2,313
-150
| -6% | -$44.8K | 0.01% | 383 |
|
|
2022
Q4 | $846K | Buy |
2,463
+672
| +38% | +$231K | 0.02% | 397 |
|
|
2022
Q3 | $339K | Sell |
1,791
-175
| -9% | -$33.1K | 0.01% | 495 |
|
|
2022
Q2 | $415K | Buy |
1,966
+797
| +68% | +$168K | 0.01% | 523 |
|
|
2022
Q1 | $391K | Buy |
1,169
+81
| +7% | +$27.1K | 0.01% | 565 |
|
|
2021
Q4 | $354K | Sell |
1,088
-50
| -4% | -$16.3K | ﹤0.01% | 615 |
|
|
2021
Q3 | $552K | Sell |
1,138
-93
| -8% | -$45.1K | 0.01% | 517 |
|
|
2021
Q2 | $572K | Buy |
1,231
+322
| +35% | +$150K | 0.01% | 525 |
|
|
2021
Q1 | $628K | Buy |
909
+590
| +185% | +$408K | 0.01% | 515 |
|
|
2020
Q4 | $236K | Buy |
319
+25
| +9% | +$18.5K | ﹤0.01% | 656 |
|
|
2020
Q3 | $204K | Buy |
+294
| New | +$204K | ﹤0.01% | 627 |
|